"Innovation is coming to health care. Yes, it's going to be digital… But there's also going to be a physical component to it – It's phys-digital, physical plus digital." -- Mohamad Makhzoumi, NEA Managing General Partner, Healthcare Fueled by remarkable breakthroughs in vaccines and new therapies, a greater understanding and treatment of overall health and new ways of deploying data to improve patient care, there are now a host of new, dynamic solutions to some of the world's biggest health challenges. But, there is also a sense of unevenness and inconsistency when it comes to opportunities and developments in the space. CNBC's Healthy Returns brought together the sharpest minds, bold pioneers and visionary leaders in the health care and biotechnology industries on March 30, 2022 to hear what's ahead for treatments and innovations, what's working, what needs to improve and what's on the horizon that will shape health care for the future. If you missed any of last week's programming, you access on-demand videos by purchasing a ticket here. |
|
|
J&J CEO'S BIG PLANS FOR A HEALTHIER FUTURE |
|
|
| In his first extended interview as CEO, Joaquin Duato, Johnson & Johnson CEO, advises health care companies to look outward to grow and innovate. Duato, the first non-U.S. born CEO at J&J and the first with dual citizenship (Spain and the U.S.), said the next decade will see more health care transformation than the past 100 years combined. "Every time we see cutting-edge innovation out there… we jump into action," Duato said to Meg Tirrell, CNBC Health & Science Reporter. "We have a very sophisticated ecosystem to be able to identify and onboard external innovation." |
|
|
TRANSFORMATIVE HEALTH TECH IDEAS FOR 2022 |
|
|
| | The last couple of years showed how reliant consumers and providers are on health care technology and investors are confident in long-term payoffs in virtual care infrastructure made apparent by reliance on telemedicine and value-based care. "Innovation is coming to health care, and it's being paired with the transition to value-based care from a system that was historically fee for service," said Mohamad Makhzoumi, NEA Managing General Partner, Healthcare, to Melissa Lee, CNBC "Fast Money" & "Options Action" Host. "The consumerization of health care is more about the patient experience but also the provider experience," said Deena Shakir, Lux Capital Partner. "The expectation is to be able to seek access to your own health data, interact with a physician asynchronously and synchronously, access lab work and diagnostics, get devices easily to care for your children… We cannot do that purely through cash pay solutions, and it will be a movement to value-based care." |
|
|
THE PROMISE AND FUTURE OF RNAI |
|
|
| The global RNAi therapeutic market, which is on the verge of treating severe and debilitating diseases, is expected to top $11.5 billion by 2027. Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals Chief Executive Officer, says Alnylam has pioneered RNAi science to develop medicines that turn off the production of specific disease-causing genes in our bodies.
"For 2022, we expect to achieve between $900 million and a billion dollars in combined net product revenues, so we're really focused on bringing our markets and medicines to patients," Greenstreet told Meg Tirrell, CNBC Health & Science Reporter. |
|
|
DELTA AIR LINES: PEOPLE-FIRST WELLNESS PROGRAM |
|
|
| Throughout the pandemic, airline employees have faced the brunt of disgruntled and unruly passengers often enraged by mask mandates. But with the federal mask mandate set to expire on April 18, Dr. Henry Ting, Delta Air Lines Chief Health Officer, says the global airline is focused on investing in the total well-being of its employees coming out of the pandemic. "Total well-being means physical, emotional, financial and social," Ting said to Phil LeBeau, CNBC Auto & Airline Industry Reporter. "We believe that in order to achieve our business goals, the best patient experience, the best safety experience and our financial performance, it really requires us to invest in our people's well-being." |
|
|
EQRX'S AMBITIOUS PLAN TO DISRUPT THE DRUG MARKET |
|
|
| Since its launch two years ago, EQRx's goal is to develop and deliver new medicines at lower prices, which has led to financial backers like Google Ventures and Andreessen Horowitz. Melanie Nallicheri, EQRx Chief Executive Officer, said EQRx will hopefully bring its medicines to the U.S. market and into retailers like CVS and Walgreens. "What we've already done is build a catalog of a large selection of more than ten treatments in development for some of the most expensive areas, such as lung cancer and chronic diseases like rheumatoid arthritis," Nallicheri told Tyler Mathisen, CNBC "Power Lunch" Co-Anchor & Vice President, Events Strategy. "We're developing new and innovative patent-protected and branded treatments." |
|
|
A CALL TO ACTION ON HEALTH EQUITY |
|
|
| | The pandemic made it obvious that communities of color face inequitable access to health care compared to white communities and two health care leaders at the Yale School of Medicine said closing these inequities takes long-term investments in health care education and building trust in health care within communities of color. "We learned from Covid that we have to go to our patients and not expect our patients to come to us," said Dr. Nancy Brown, Yale School of Medicine Dean to Contessa Brewer, CNBC Correspondent. "To make vaccines accessible, we had to develop trust in vaccines through weekly communications with our community leaders… and develop pop-up clinics to provide vaccinations in churches and community health settings."
"The idea of creating a health care system that is trustworthy is really important… Have people who are trusted members of the community talk about health care and educate the community," said Dr. Gary Désir, Yale School of Medicine Department of Internal Medicine Chair. |
|
|
2022 BIOTECH INVESTING FORECAST |
|
|
| 2020 and 2021 shaped out to be different years for return on investment for the biotechnology industry with 2020 being flooded with capital and 2021 becoming oversaturated, said Dr. Christiana Bardon, MPM Capital Co-Managing Partner. However, Bardon says 2022 and the next 30 years will likely see investment in biotech skyrocket due to innovation and growth. "It looks like a great time for investing in biotech… We have a number of companies in our sector that are trading at cash," Bardon said to Leslie Picker, CNBC Finance and Investing Reporter. "But more importantly, what I see is that the long-term prospects of this industry look as great as ever." |
|
| WALGREENS: A GROWING HEALTH CARE FOOTPRINT |
|
|
| Americans turned to major drugstore chains like Walgreens for testing, vaccinations and personal care items during the pandemic. But Rosalind Brewer, Walgreens Boots Alliance Chief Executive Officer, says the company is investing in automation, fulfillment centers and primary care physicians to turn Walgreens into an all-inclusive neighborhood health care destination. "We're doing all of this work, so that the pharmacist has an easier job, so that they can get back to being front and center, building a relationship with that patient and interacting the way they were trained — the work that they love to do," she said to Bertha Coombs, CNBC Reporter. |
|
|
All panels and sessions are available through Friday, April 15th. Register now to access Healthy Returns On Demand. |
|
|
|
Tidak ada komentar:
Posting Komentar